Osteoarthritis (OA) is the most common form of arthritis. It is characterized by cartilage destruction and bone remodeling, mediated in part by synovial fibroblasts (SFs). Given the functional significance of cadherins in these cells, we aimed at determining the role of genetic variants of N-cadherin (CDH2) in OA of the knee and hip. Six single-nucleotide polymorphisms in the genomic region of the CDH2 gene were genotyped in 312 patients with OA and 259 healthy control subjects. Gene expression of CDH2 was analyzed by qRT-PCR. Liquid chromatography-mass spectrometry was used to identify a transcription factor isolated by DNA pulldown. Its potential for binding to gene variants was examined by electrophoretic mobility shift assay, enzyme-linked immunosorbent assay, and chromatin immunoprecipitation. Genetic analysis identified a polymorphism located in the CDH2 promoter region to be associated with risk of OA. The minor allele of rs11564299 had a protective effect against OA. Compared to carriers of the major allele, carriers of the minor allele of rs11564299 displayed increased Ncadherin levels in SFs. Based on in silico analysis, the minor allele was predicted to generate a novel transcription factor binding site, Direct-binding assays and mass spectrometric analysis identified hnRNP K as binding selectively to the minor allele. In summary, a CDH2 promoter polymorphism influences the risk of OA, and hnRNP K was found to be involved in the regulation of elevated N-cadherin expression in patients with OA carrying the minor allele of rs11564299.-
Osteoarthritis (OA) is the most common form of arthritis. Cartilage destruction and bone remodeling characterize this painful and disabling disease. OA is a complex disease, and both environmental and genetic factors play a role in disease susceptibility. Several genetic loci with genome-wide significance have been identified for hip and knee OA (1) (2) (3) . Three important points came up in these genetic studies: first, the effects of the common variants are low to moderate; second, differences between European and Asian study samples have been reported; and third, joint-specific genetic effects are involved (4, 5) . Despite the replication of genetic risk variants, the molecular pathogenesis is still poorly understood. However, there is growing evidence that fibroblasts of the synovial membrane from OA patients [OA synovial fibroblasts (OASFs)] play an important role. It has been shown that activated OASFs are capable of migrating into and destroying the cartilage (6) , thereby contributing to disease progression and severity.
Cadherins are a family of structurally related, calciumdependent cell-cell adhesion proteins that play important roles in cell adhesion and migration in processes ranging from embryogenesis to cancer metastasis (7) . Human in vitro and murine in vivo studies have established a critical role of cadherin 11 in the development and architecture of the synovium and in modulating the capacity of synovial fibroblasts (SFs) to produce cytokines, chemokines, and other inflammatory factors (8, 9) . Less is known about the role of N-cadherin, which is encoded by the CDH2 gene (10) , has been found to be coexpressed with cadherin 11 on murine 1 These authors contributed equally to this work. 2 Correspondence: Institute of Pathology, University of Regensburg, Franz-Josef-Strauss-Allee 11, D-93053 Regensburg, Germany. E-mail: anja.bosserhoff@klinik.uni-regensburg.de doi: 10.1096/fj.13-238295
Abbreviations: ChIP, chromatin immunoprecipitation; dsoligonucleotides, double-stranded oligonucleotides; ELISA, enzyme-linked immunoabsorbent assay; EMSA, electrophoretic mobility shift assay; hnRNP K, heterogeneous nuclear ribonucleoprotein K; HWE, Hardy-Weinberg equilibrium; LD, linkage disequilibrium; OA, osteoarthritis; OASF, osteoarthritis synovial fibroblast; PCR, polymerase chain reaction; qRT-PCR, quantitative reverse transcription polymerase chain reaction; SF, synovial fibroblast; SNP, single-nucleotide polymorphism SFs (11) , and has been reported to suppress or promote invasion in different kinds of cancer. For example, the loss of N-cadherin has been reported to lead to reduced cell-cell adhesion in osteosarcoma. Therefore, the absence of N-cadherin promotes metastasis in these cells (12) . In contrast, it has been shown that N-cadherin expression in, for example, melanoma cells or pancreatic cancer cells leads to increased metastasis; therefore, overexpression promotes migration (13) (14) (15) . Here, we describe changes of N-cadherin expression at the mRNA level in OASFs in association with a singlenucleotide polymorphism (SNP) in the N-cadherin promoter. Bringing together both genetic association studies and functional data could lead to the identification of novel pathways of OA onset and progression.
MATERIALS AND METHODS

Study population
A total of 571 Slovak individuals (127 males, 444 females) were included in the study: 312 patients with OA (60 males, 252 females) and 259 healthy control subjects (67 males, 192 females). OA disease status of the knee, hand, and hip were clinically and radiographically ascertained. The control subjects were selected by clinical exclusion of arthritic or degenerative symptoms. Further phenotype details are shown in Table 1 . Our study case patients and control subjects did not differ in gender, but the latter were significantly younger (PϽ0.001).
Subjects' written consent was obtained according to the current Declaration of Helsinki. The study was approved by the ethics committees of the Slovakia National Institute of Rheumatic Diseases (Piestany, Slovakia) and the University of Regensburg (Regensburg, Germany).
Marker selection and genotyping
SNPs in the CDH2 genomic region (NM_001792.3) on chromosome 18 were selected to cover the gene without redundancy with respect to linkage disequilibrium (LD) structure: 1 SNP at the distal promoter (rs11083271), 1 SNP at the proximal promoter (rs11564299), 1 SNP in intron 2 (rs11564392), and 1 SNP at the 3= end of the gene (rs2871593). In addition, rs4131805, located 302 kb upstream of the CDH2 5= end, was included because of a reported association with bone density and geometry (16) . Therefore, 542 kb of the genomic region was analyzed with Ն1 SNP in each distinct LD block (Fig. 1A) . After a first round of association testing, SNP rs11083255 was analyzed as an additional marker in the CDH2 promoter region. For information on all SNP markers analyzed, see Table 2 .
Genomic DNA was isolated from whole-blood specimens with the PureGene DNA Blood Kit (Qiagen, Hilden, Germany). DNA samples were genotyped with 5= exonuclease TaqMan technology (Life Technologies; Applied Biosystems, Foster City, CA, USA), according to the manufacturer's instructions. In brief, for each genotyping experiment, 10 ng DNA was used in a total volume of 5 l containing 1ϫ TaqMan Genotyping Master Mix. Polymerase chain reaction (PCR) and post-PCR end point plate reading was performed on an Applied Biosystems 7900HT Real-Time PCR System. Sequence Detection System 2.3 software (Life Technologies) was used to assign genotypes applying the allelic discrimination test. Case and control DNA were genotyped together on the same plates with duplicates of samples (10%) to assess intraplate and interplate genotype quality. No genotyping discrepancies were detected. Assignment of genotypes was performed by a person without knowledge of the proband's affection status.
Cell culture, RNA extraction, and real-time quantitative reverse transcription PCR (qRT-PCR) analysis
Synovial tissue specimens were obtained from patients with OA immediately after the knee joint capsule was opened (17) . Synovial cells from patients with OA were cultured in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich, Munich, Germany), 10% fetal calf serum (FCS; PAN Biotech, Aidenbach, Germany), and penicillin and streptomycin (P/S) (PAA, Piscataway, NJ, USA). The same medium was used to grow the cell lines HSE (immortalized rheumatoid SFs) and K4Im (immortalized normal SFs), which were kindly provided by Prof. W. K. Aicher (University of Tübingen, Tübin-gen, Germany). Total cellular RNA was isolated from cultured cells with the RNeasy kit (Qiagen), and cDNAs were generated by reverse transcription. In parallel, genomic DNA from cultured cells for genotyping was isolated with the QIAamp DNA Mini Kit (Qiagen). qRT-PCR was performed with SYBR Green master mix (Qiagen), with the primer pair 5=-TGGAT-GAAGATGGCATGG-3= and 5=-AGGTGGCCACTGTGCT-TAC-3=, targeting exon A to exon B of CDH2. Relative gene expression was normalized to ␤-actin mRNA levels by using the comparative cycle threshold (C t ) method. The Mel-Im cell line was used as a calibrator sample.
Preparation of nuclear extracts
Nuclear extracts from OASFs were prepared by using the method of Dignam et al. (18) .
Enzyme-linked immunoabsorbent assay (ELISA)
For quantitative measurement of the binding capacity of transcription factors, a sandwich ELISA was established based on a previously published protocol (19) . 5=-Biotinylated (Btn) forward oligonucleotides that contained either variant A [5=-(Btn)-TATTCCTTCTTGTAA-3=] or variant G of rs11564299 [5=-(Btn)TATTCCTCCTTGTAA-3=] were annealed overnight to reverse complementary, nonbiotinylated oligonucleotides (5=-TTACAAGAAGGAATA-3= and 5=-TTACAAGGAGGAATA-3=, respectively) and then were bound onto streptavidincoated plates. After 3 washes of the plates with PBS, nonspecific binding was blocked with incubation buffer (MIA ELISA; Roche Applied Sciences, Mannheim, Germany) for 1 h. Nuclear proteins from HSE cells, 6 g in 150 l of incubation buffer, were allowed to bind to the oligonucleotides for 1 h. For displacement analysis, double-stranded oligonucleotides (ds-oligonucleotides) without the biotin label were incubated with the nuclear extracts for 10 min before incubation on the plate. The plates were then washed 3 times with incubation buffer, followed by incubation with a specific antibody against ETS-1 (1:500; Novocastra; Leica Biosystems, Wetzlar, Germany) or heterogeneous nuclear ribonucleoprotein K (hn-RNP K; 1:500; Acris Antibodies, San Diego, CA, USA) for 1 h. After 3 washes with incubation buffer, a secondary antibody, anti-mouse or anti-rabbit (1:1000; Cell Signaling Technology, Danvers, MA, USA) conjugated with horseradish peroxidase, was added for 30 min. The binding was measured by using ABTS solution (Roche Applied Sciences).
Pulldown assay
5=-Biotinylated forward oligonucleotides containing either variant A or G of rs11564299 were annealed overnight to their respective complementary, nonbiotinylated strands [5=-(Btn)TATTCCTTCTTGTAA-3= and 5=-TTACAAGAAGGAATA-3=; and 5=-(Btn)TATTCCTCCTTGTAA-3= and 5=-TTACAAGGAGGAATA-3=]. Streptavidin beads (GE Healthcare Europe GmbH, Freiburg, Germany) were washed with 1 ml of ice-cold PBS. Then, the beads were incubated with the annealed 5=-biotinylated oligonucleotides overnight. Nuclear extracts from the HSE cells were precleared by incubation with streptavidin beads overnight. On the next day, the precleared lysate was incubated with the oligonucleotides bound to streptavidin beads for 4 h. The samples were analyzed by SDS-PAGE, followed by silver staining. The bands selectively occurring in the samples of the minor variant of rs11564299 were cut out and analyzed by mass spectrometry (MS).
MS
Respective bands were excised and washed according to Shevchenko et al. (20) with slight modifications. Briefly, gel pieces were washed 3 times alternately with 50 l of 50 and 25 mM NH 4 HCO 3 in 50% acetonitrile. Subsequently, the gel slices were dried in a vacuum centrifuge. Trypsin solution (5 l; 12.5 ng/l in 50 mM NH 4 HCO 3 ) was added to each gel piece and incubated at 37°C overnight for in-gel digestion. The obtained peptides were eluted with 20 l of 5% formic acid and subjected to nano-LC-MS/MS-analysis on an Ultimate 3000 nano-HPLC system (Dionex GmbH, Idstein, Germany). The samples were preconcentrated on a 300 m i.d., 5 mm C18-PepMap precolumn (5 m, 300 Å; Thermo Fisher Scientific, Idstein, Germany), with 0.1% formic acid and a flow rate of 40 l/min. The peptides were then separated on a 75 m i.d., 15 cm, C18-PepMap-column (flow rate 300 nl/min; Thermo Fisher Scientific), with a 1 h binary gradient from 4 to 40% of solvent B (solvent A: 0.1% formic acid; solvent B: 0.1% formic acid in acetonitrile). The nano-HPLC was directly coupled to a quadrupole time-of-flight (QTOF) mass spectrometer (QStar XL; AB Sciex, Darmstadt, Germany) acquiring 1 full MS and 2 MS/MS spectra of the most intense ions in the respective full-MS scan, repeatedly. The MS/MS spectra were searched against the Uniprot database with the Mascot Daemon and the Mascot algorithm (version 2.2; Matrix Science Ltd., London, UK), with trypsin used as the protease with a maximum of 1 missed cleavage site, oxidation of methionine as a variable modification, and 0.2 Da tolerance for MS and MS/MS signals. Only proteins with Ն2 significantly scored peptide spectra that passed manual inspection were considered to be positive identifications.
Electrophoretic mobility shift assay (EMSA)
Two double-stranded oligomeric binding sites with either variant A (5=-TACAAGAAGGAA-3=) or variant G (5=-TA-CAAGGAGGAA-3=) of rs11564299 were generated. The dsoligonucleotides were end labeled with T4 polynucleotide kinase (Roche Applied Sciences) and [ 32 P]ATP[␥P] (Amersham-GE Healthcare, Munich, Germany). Band shifts were performed by incubating 5 g recombinant hnRNP K (Cusabio Biotech, Wuhan, China) in 5ϫ mobility shift buffer [1 g of poly(dI-dC)(dI-dC), 40% glycerol, 25 mM MgCl 2 , 1 mM EDTA, 25 mM dithiothreitol, 250 mM KCl, and 25 mM HEPES/KOH, pH 7.9) with the DNA probe for 10 min before separation on a 6% nondenaturing polyacrylamide gel. DNA-protein complexes were resolved on a nondenaturing polyacrylamide gel at 250 V, 50 mA, and 100 W for 1.5 h (21).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as described by the manufacturer (ChIP-IT Enzymatic; Active Motif, La Hulpe, Belgium). Specific antibodies against hnRNP K (Sigma-Aldrich), ETS-1 (Novocastra), polymerase II (Active Motif), and IgG (Active Motif) were used. For qRT-PCR, primers spanning the region around rs11564299 were designed (hCDH2 rs11564299 forward, 5=-CTTCTTGTAATCAGAGGCC-3=, and hCDH2 rs11564299 reverse, 5=-ATTGTTTTAGCATCTTGCC-3=). For quantification of the positive control, commercially available GAPDH primers (Active Motif) were used.
Statistical analyses and bioinformatics tools
Differences between dichotomous traits were calculated by 2 test. Differences in continuous variables between groups were calculated with a 2-tailed t test for normally distributed values or with the nonparametric Wilcoxon rank sum test for variables that failed normal distribution, as determined by the Shapiro-Wilk test. Expression data between the 3 genotype groups were compared by Kruskal-Wallis test. Association analysis was carried out in a logistic regression model with gender as a covariate. When age of onset was included as a covariate, for the controls age at inclusion was used. Prevalence ORs with their 95% CIs were reported. Values of P Ͻ 0.05 were considered significant. To determine whether the genotypes of case patients and control subjects of all SNPs deviated from Hardy-Weinberg equilibrium (HWE), actual and predicted genotype counts of both groups were compared by an exact test (22) . Association analyses were performed with PLINK 1.07 (23) , and the statistical software package JMP 7.0.2 (SAS Institute, Inc., Cary, NC, USA) was used for other analyses. For LD testing, HaploView 4.2 was used (24) with HapMap phase II data from releases 22, 24, and 27 (25) . MatInspector 8.04, and SNPInspector 2.2 (Genomatix Software GmbH, Munich, Germany) were used to analyze the potential functional effects of SNPs on transcription factor binding sites.
RESULTS
Testing for genetic association
All genotyped markers fulfilled our criteria of a Ն95% call rate and showed no deviation from HWE ( Table 3 ).
The 5 SNPs genotyped initially were not in tight LD (maximum r 2 ϭ0.03 in the entire study sample of 571 persons). There was a significant association (Pϭ1.5ϫ 10 Ϫ3 ) between rs11564299 and risk of OA in logistic regression analysis after adjustment for gender. Significance decreased to P ϭ 5.0 ϫ 10 Ϫ3 after additional adjustment for age of recruitment (Table 3 ). In the fully adjusted model, SNP rs11083271 was nominally associated with OA risk (Pϭ0.02; Table 3 ). Because rs11564299 is localized in the promoter region 2583 bp upstream of the CDH2 5= end, we searched the HapMap data for polymorphisms closer to the CDH2 transcription start site. The SNP marker rs11083255 is localized 1719 bp upstream of CDH2 and was included in a second round of genotyping. Both rs11564299 and rs11083255 were in weak LD in our study sample (r 2 ϭ0.215). A significant association between rs11083255 and OA risk was detected (Pϭ1.2ϫ10
Ϫ3 for logistic regression adjusted for gender; Pϭ1.1ϫ10 Ϫ2 for logistic regression adjusted for gender and age at recruitment; Table 3 ). The effect direction for both SNPs was the same, with a protective effect of the minor allele (Table 3) . Taking multiple testing with a total of 6 markers into account, only rs11564299 showed significant association with OA risk in our study (Pϭ5.0ϫ10 Ϫ3 ϫ6 testsϭ0.03). Conditional logistic regression analysis with each nominally associated SNP showed that rs11083255 and rs11564299 were not fully independently associated with OA risk (Pϭ0.040, ORϭ0.69 for rs11564299, after adjustment for rs11083255; Pϭ0.166, ORϭ0.61 for rs11083255, after adjustment for rs11564299)-that is, loss of significance of Ն1 order of magnitude was observed. As assumed by LD, rs11083271 did not fully explain the association results for rs11564299 (Pϭ0.018, ORϭ0.67) and rs11083255 (Pϭ0.020, ORϭ0.46). Because our study sample included different phenotypes of OA (Table 3) , we performed separate analyses on samples of knee OA and hip OA. A comparison of 68 patients with isolated knee OA with 259 control subjects showed that 3 markers from the combined analysis (rs11083255, rs11564299, and rs11083271) remained significantly associated (logistic regression using gender and age at inclusion as covariates; Pϭ0.016, Pϭ0.036, and Pϭ0.042, respectively). For hip OA (nϭ 74 cases), no association was detected (Pϭ0.639, Pϭ 0.071, and Pϭ0.887, respectively).
Expression analysis
A total of 29 synovial cell specimens were available from patients with knee OA. Comparison of CDH2 mRNA expression levels between heterozygotes (nϭ3) and homozygotes (nϭ26) for the major allele of rs11083255 did not reach the significance level (Pϭ0.43). The 3 genotypes of rs11564299 were strongly associated with CDH2 mRNA expression (Pϭ0.0086). Comparison between rs11564299 heterozygotes (nϭ9) and homozygotes (nϭ19) for the major allele yielded P ϭ 0.0073 (Fig. 1B) . For both SNPs, the mean expression of CDH2 was higher in carriers of the minor alleles (e.g., rs11564299: heterozygotes, meanϭ1.04Ϯ0.94; homozygotes, meanϭ 0.26Ϯ0.33). 
In silico data
That the G allele of rs11564299 was associated with elevated CDH2 mRNA levels in OASF led to the hypothesis that this allele may generate a novel transcription factor binding site. In silico analysis with Genomatix (Genomatix Software GmbH) predicted the loss of a TEF (26) binding site and a gain in sites for ETS-like transcription factors (27) and ZNF35 (28) .
Analysis of a potential transcription factor binding site
A quantitative ELISA with ds-oligonucleotides containing either variant A or G of rs11564299 as bait was established to verify the predicted ETS-like binding site. After incubation with nuclear proteins and detection with a specific ETS-1 antibody and peroxidase-labeled secondary antibodies, no differences in binding efficiency to one of the variants were observed (Fig. 2A) . Therefore, ETS-1 was excluded as a transcription factor binding selectively to the minor allele of rs11564299. Subsequently, a pulldown assay was performed for identification of the transcription factor responsible for the higher CDH2 mRNA levels observed with the minor rs11564299 allele. The pulldown was performed with nuclear extracts of the cell line HSE, which had tested heterozygous for rs11564299, by using the specific oligonucleotides for alleles A and G of rs11564299. Pulled down proteins were separated on an acrylamide gel and stained silver, followed by excision, tryptic digestion, and MS analysis of those protein bands that had been pulled down selectively with ds-oligonucleotides containing variant G (Fig. 2B) . This method revealed hnRNP K as a potential binding protein.
Expression of hnRNP K in early (P3) and late (P8) passages of OASFs was determined by qRT-PCR, and no significant differences were observed between the different groups (Fig. 2C ). For analysis of differential binding of hnRNP K to the minor allele (G) compared to the major allele (A) of rs11564299, a quantitative ELISA with a specific hnRNP K antibody was established. The ELISA showed that hnRNP K bound only to ds-oligonucleotides containing variant G, but not to those containing variant A (Fig. 3A) . The binding was inhibited by preincubation with ds-oligonucleotides containing variant G but not variant A (Fig. 3A) . As shown before, performing the ELISA with an ETS-1 antibody revealed no differential binding of ETS-1 to ds-oligonucleotides containing either variant of the SNP rs11564299 ( Fig. 2A) . As a negative control, a setting with the forward biotinylated ssDNA oligonucleotides was performed, but did not show any binding of hnRNP K to the ssDNA (data not shown). EMSAs of similar oligonucleotides yielded the same results. A shift was observed only for probes carrying variant G after incubation with recombinant hnRNP K (Fig. 3B ). This result showed that hnRNP K bound exclusively to the minor allele of rs11564299, indicating that hnRNP K may be responsible for elevated CDH2 mRNA expression. To further elucidate the binding of hnRNP K to the minor variant of rs11564299, a ChIP assay was performed. Antibodies against ETS-1 (positive control 1), pol II (positive control 2), and IgG (negative control) were used in addition to the anti-hnRNP K antibody. The ChIP assay was performed with HSE cells, which are heterozygous for rs11564299, and K4Im, a cell line of immortalized SFs that are homozygous for the major allele of rs11564299. hnRNP K bound only to chromatin in HSE cells, whereas no binding was observed when the homozygous wild-type K4Im cells were tested (Fig. 3C ). These findings confirmed that hnRNP K bound exclusively to the Ncadherin promoter in the presence of the minor allele of rs11564299, therefore making hnRNP K a candidate for inducing the elevated levels of N-cadherin.
DISCUSSION
Genetic association studies have shown that SNPs contribute significantly to the susceptibility and severity of many diseases (29) . Also, associations of genetic variants with OA onset and progression have been published (2, 30) . As shown before, SNPs in the promoter region of a gene can influence disease susceptibility (31, 32) . Our results indicate that CDH2 SNP rs11564299 influences susceptibility to OA prevalence, as the minor G allele is more common among the control population than the OA population. We found that the allelic state of rs11564299, which is located 2583 bp upstream of the CDH2 transcription start site, significantly affected mRNA expression levels of CDH2 in SFs, with the AG heterozygotes (HSE cells) expressing significantly more CDH2 than the AA homozygotes (K4Im cells). This result indicates stronger activity of the CDH2 promoter in patients carrying the minor allele, probably caused by an allele-specific transcription factor binding site. However, none of the transcription factors predicted in silico to bind to the variant promoter sequence showed differential binding to the minor allele of rs11564299. Rather, MS analysis identified hnRNP K as a factor that bound exclusively to the G allele of rs11564299 and not to the A allele. hnRNP K is one of the major pre-mRNA binding proteins. It has also been described to bind dsDNA and to act as a transcription factor (33) . Binding of hnRNP K was confirmed by a specific ELISA and ChIP. Thus, hnRNP K appears to contribute to the increased N-cadherin expression levels in SFs carrying the G allele of rs11564299. As N-cadherin is a core component of adherens junctions, the increased levels of it may affect cell-cell contacts, tissue architecture, and cell motility (34, 35) . It has been described before that N-cadherin levels are critical for cell invasion and that N-cadherin re-expression in glioma cells and in human arterial smooth muscle cells leads to less migration (36, 37) . Therefore, higher N-cadherin levels in SFs may lead to a decreased migratory potential of the cells. As shown by Schubert et al., (6) migration of SF into cartilage leads to the degradation of the extracellular matrix and cartilage loss. Thus, inhibition of migration by enhanced cell-cell contact may prevent or reduce cartilage destruction. All evidence combined, our study implicates for the first time CDH2 encoding N-cadherin as a susceptibility gene for OA, especially of the knee. Some limitations of our study should be discussed. First, we had no replication study for the genetic association data, and therefore our finding of rs11564299 as a risk factor for OA susceptibility could be a false positive. However, the apparent link between rs11564299 allelic state and CDH2 mRNA expression lends functional support to this hypothesis. Second, the effect size of the rs11564299 minor allele on OA risk is small (ORϭ0.63, i.e., ϳ1.6 times increased risk in carriers of the major allele). However, it has become obvious that common variants are often associated with OR Ͻ 1.5 (38) . Third, because the control subjects were selected by clinical exclusion of arthritic or degenerative diseases, apparent OA was excluded. However, the preclinical state of joint disorders within the controls could have affected the association results. Fourth, because of our marker selection, we did not fully cover the whole CDH2 gene when tagging SNPs. This deficiency is one that could be solved by screening existing genome-wide association data on OA (2). Since SFs are only 1 candidate cell type in the joint that is potentially responsible for OA onset and progression, future studies should expand N-cadherin analysis to other cells and their interaction within the joint. The exact role of N-cadherin for OA susceptibility has yet to be defined. Further analyses should be aimed at the interaction of genetic variants in CDH2 with known risk factors for OA, such as age, increased body-mass index, mechanical stress, and microinjuries of the joint.
